Allergan (NYSE:AGN) issued an update on its FY 2019 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $16.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.72. The company issued revenue guidance of $15.4-15.6 billion, compared to the consensus revenue estimate of $15.34 billion.Allergan also updated its FY19 guidance to >$16.55 EPS.
A number of equities research analysts recently issued reports on the stock. Sanford C. Bernstein lowered shares of Allergan from an outperform rating to a market perform rating and set a $166.08 price objective for the company. in a report on Tuesday, July 16th. Cantor Fitzgerald reduced their price target on shares of Allergan from $180.00 to $125.00 and set a neutral rating on the stock in a research report on Wednesday, June 12th. JPMorgan Chase & Co. set a $200.00 price target on shares of Allergan and gave the stock a buy rating in a research report on Wednesday, June 19th. Royal Bank of Canada set a $178.00 price target on shares of Allergan and gave the stock a hold rating in a research report on Wednesday, June 26th. Finally, ValuEngine cut shares of Allergan from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $178.10.
NYSE:AGN traded down $0.65 during mid-day trading on Wednesday, hitting $158.84. The stock had a trading volume of 4,747,570 shares, compared to its average volume of 3,502,244. The firm’s 50-day simple moving average is $159.30. The company has a market capitalization of $52.28 billion, a P/E ratio of 9.52, a PEG ratio of 1.51 and a beta of 1.63. Allergan has a twelve month low of $114.27 and a twelve month high of $197.00. The company has a quick ratio of 0.60, a current ratio of 0.71 and a debt-to-equity ratio of 0.32.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Tuesday, August 13th will be issued a dividend of $0.74 per share. The ex-dividend date is Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a yield of 1.86%. Allergan’s payout ratio is currently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.